Palavras-chave
Qualidade de vida
Medidas de resultados relatados pelo paciente
Impacto psicossocial
Terapêutica
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar e sintetizar os fatores clínicos, terapêuticos e psicossociais que influenciam a qualidade de vida de indivíduos com urticária crônica induzida. Métodos: Trata-se de uma revisão integrativa da literatura, conduzida nas bases PubMed, Scopus, SciELO e Web of Science. Foram incluídos 24 artigos publicados a partir de 2017, selecionados rigorosamente conforme as diretrizes do fluxograma PRISMA. Resultados: A doença impõe um fardo multidimensional, com escores basais indicando impacto severo na qualidade de vida e elevada refratariedade terapêutica. O comprometimento engloba redução da produtividade e severas repercussões psicossociais, como disfunção sexual e prejuízo espiritual. Identificou-se que os instrumentos tradicionais de avaliação tendem a subestimar o impacto real da doença ao falharem em capturar o fardo comportamental gerado pela hipervigilância e evitação de gatilhos. Considerações finais: Pode-se considerar que o impacto da condição é profundo e multifacetado, sendo determinado pelo controle clínico. O estudo ressalta a necessidade de adoção de instrumentos de resultados relatados pelos pacientes específicos para uma avaliação fidedigna e manejo personalizado.
Referências
BAUDY V, et al. Impact of Chronic Spontaneous or Inducible Urticaria on Occupational Activity. Acta Dermato-Venereologica, 2024; 104: e36122.
BUMBĂCEA RS, et al. Management problems in severe chronic inducible urticaria: Two case reports. Experimental and Therapeutic Medicine, 2019; 18(2): 960-963.
CAN PK, KOCATÜRK E. Avaliação das respostas ao tratamento com as ferramentas recomendadas em pacientes com dermografismo sintomático. Turkderm-Turk Arch Dermatol Venereology, 2019; 53(4): 139-143.
CHEN Y, et al. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria. International Archives of Allergy and Immunology, 2023; 184(8): 768-777.
DIAS DE CASTRO E, et al. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal. European Annals of Allergy and Clinical Immunology, 2018; 50(6): 263-268.
DIAS G, et al. Clinical experience of a chronic urticaria referral university center. European Annals of Allergy and Clinical Immunology, 2020; 52(2): 78-84.
DORTAS JUNIOR SD, et al. Spiritual well-being and quality of life are impaired in chronic urticaria. European Annals of Allergy and Clinical Immunology, 2021; 53(5): 221-227.
HAWRO T, et al. The Urticaria Activity Score-Validity, Reliability, and Responsiveness. The Journal of Allergy and Clinical Immunology: In Practice, 2018; 6(4): 1185-1190.
KILIC A, et al. Sexual Functions are Impaired in Males and Females with Chronic Spontaneous and Inducible Urticaria; A Controlled Study. Dermatology Practical & Conceptual, 2025; 15(1): e2025001.
KOCATÜRK E, et al. Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria. World Allergy Organization Journal, 2019; 12(1): 100008.
KULTHANAN K, et al. Checklist for a complete chronic urticaria medical history: an easy tool. World Allergy Organization Journal, 2017; 10(1): 1-5.
KUMARAN MS, et al. Decoding the variability in clinical and laboratory profiles of Chronic Inducible Urticaria vs. Chronic Spontaneous Urticaria - a retrospective study from a tertiary care center. Archives of Dermatological Research, 2024; 316(10): 703.
LEE SJ, et al. Natural course and prognostic factors of chronic urticaria in Korean children: A single center experience. Asian Pacific Journal of Allergy and Immunology, 2019; 37(1): 25-30.
MAO Y, et al. Clinical difference between single subtype and mixed subtype chronic urticaria: A retrospective study. Indian Journal of Dermatology, Venereology and Leprology, 2022; 88: 167-173.
MASTROLONARDO M, et al. Long term treatment with omalizumab in adolescent with refractory solar urticaria. Italian Journal of Pediatrics, 2021; 47(1): 195.
MAURER M, et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organization Journal, 2018; 11(1): 31.
METZ M, et al. A randomized, double-blind, placebo-controlled, crossover study to evaluate the efficacy of hydroxyzine... for treating chronic cold urticaria. Clinical and Experimental Dermatology, 2018; 43(8): 871-876.
OTT, H. Chronische Urtikaria im Kindesalter: Rationale Diagnostik und Therapie. Der Hautarzt, v. 68, n. 7, p. 571-582, jul. 2017. DOI: 10.1007/s00105-017-3985-5.
RUJITHARANAWONG C, et al. Natural history and clinical course of patients with dermographism in a tropical country: a questionnaire-based survey. Asia Pacific Allergy, 2022; 12(4): e39.
SÁNCHEZ-BORGES M, et al. The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organization Journal, 2021; 14(6): 100546.
TERHORST-MOLAWI D, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy, 2022; 78(5): 1364-1367.
WELLER K, et al. Dermographism control test: Development and validation... Journal of the European Academy of Dermatology and Venereology, 2018; 32(8): 1335-1342.
WELLER K, et al. Development of the symptomatic dermographism quality of life questionnaire. Clinical and Translational Allergy, 2025; 15(1): e70038.
ZUBERBIER T, et al. The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis,
comorbidities, quality of life, and management. World Allergy Organization Journal, 2021; 14(5): 100533.